EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access · CC BY 4.0

Reproductive Safety Issues of Novel Small Molecules for the Treatment of Inflammatory Bowel Disease: A Systematic Review

Niloufar Monfared, Matthew Gold, Isabel Carbery iD, Robyn Laube, Christian P Selinger iD

Journal of Clinical Medicine · 20.12.2023 · 13 (1) · 34

DOI: 10.3390/jcm13010034 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 20.12.2023. Verfasst von Niloufar Monfared und 4 weiteren Autor:innen. Beteiligte Einrichtung: Leeds Gastroenterology Institute, Leeds Teaching Hospitals, Leeds LS9 7TF, UK. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Maintenance of remission during pregnancy is vital for women with inflammatory bowel disease (IBD). The antenatal safety of novel small molecules for IBD is yet to be ascertained. We aimed to describe the current evidence on reproductive data regarding small-molecule drugs. We performed a systematic review searching Embase Classic + Embase and Ovid MEDLINE for reproductive outcomes for tofacitinib, filgotinib, upadacitininb, and ozanimod. Additionally, we asked the manufacturers for available data on file regarding reproduction. We analysed data from 10 sources; six studies and four manufacturer reports were identified from our search. Significant malformation risks were reported for tofacitinib, filgotinib, upadacitininb, and ozanimod in animal studies. In 126 tofacitinib-exposed pregnancies, there were 55 live births with 2 congenital malformations and 1 serious infant infection, 14 terminations, 15 miscarriages, and 42 outcomes unknown. In 50 filgotinib-exposed pregnancies, there were 20 healthy babies, 1 congenital malformation, 9 terminations, 10 miscarriages, and 10 outcomes unknown. In 78 upadacitinib-exposed pregnancies, there were 30 healthy babies, 15 terminations, 15 miscarriages, and 18 outcomes unknown. In 60 ozanimod-exposed pregnancies, there were 31 live births with 1 congenital malformation, 1 case of intra-uterine growth restriction, 1 case of neonatal icterus, 13 terminations, 9 miscarriages, and 8 unknown outcomes. Animal data suggest significant risks of malformations for tofacitinib, filgotinib, upadacitininb, and ozanimod. Human data from clinical trials and real-world observations do not show concerning data so far, but these are very limited. Currently, alternative treatments should be used for IBD during pregnancy.

Schlagwörter

Stichwörter der Autor:innen

inflammatory bowel diseasenovel small moleculepregnancy

Autor:innen und Institutionen

  • Leeds Gastroenterology Institute, Leeds Teaching Hospitals, Leeds LS9 7TF, UK.

ORCID-Profile: Isabel Carbery, Christian P Selinger

Zitieren

APA

Monfared, N., Gold, M., Carbery, I., Laube, R., & Selinger, C. P. (2023). Reproductive Safety Issues of Novel Small Molecules for the Treatment of Inflammatory Bowel Disease: A Systematic Review. Journal of Clinical Medicine, 13(1), 34. https://doi.org/10.3390/jcm13010034

Vancouver

Monfared N, Gold M, Carbery I, Laube R, Selinger CP. Reproductive Safety Issues of Novel Small Molecules for the Treatment of Inflammatory Bowel Disease: A Systematic Review. Journal of Clinical Medicine. 2023;13(1):34. doi:10.3390/jcm13010034

BibTeX
@article{Monfared2023,
  author = {Monfared, Niloufar and Gold, Matthew and Carbery, Isabel and Laube, Robyn and Selinger, Christian P},
  title = {Reproductive Safety Issues of Novel Small Molecules for the Treatment of Inflammatory Bowel Disease: A Systematic Review},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {13},
  number = {1},
  pages = {34},
  doi = {10.3390/jcm13010034}
}
Kostenlos starten →